Latest Treatment Advances for Mesothelioma
Executive Summary
Latest treatment advances for mesothelioma represent the most significant transformation in standard of care in two decades. In March 2025, the American Society of Clinical Oncology (ASCO) published its first guideline update since 2018, reflecting data from 110 peer-reviewed studies and establishing three first-line systemic regimens: platinum-pemetrexed chemotherapy, nivolumab plus ipilimumab immunotherapy, and pembrolizumab plus chemotherapy.[1] Five-year data from the CheckMate 743 trial confirmed durable survival benefit with dual checkpoint blockade, more than doubling the 5-year survival rate versus chemotherapy (14% vs. 6%).[2]
The surgical landscape has shifted decisively toward lung-sparing pleurectomy/decortication (P/D) over the more aggressive extrapleural pneumonectomy (EPP), and the FDA approved pembrolizumab-based chemoimmunotherapy in September 2024.[3] Several novel agents are advancing through the pipeline, including the ADI-PEG 20 (pegargiminase) arginine-depletion therapy, tumor treating fields (TTFields), mesothelin-targeted CAR-T cells, the UV1 telomerase vaccine, and the volrustomig regimen under study in the eVOLVE-Meso phase III trial.
Germline BAP1 testing is now recommended for all mesothelioma patients, reflecting recognition of a hereditary cancer syndrome with unique prognostic implications, and blood-based liquid biopsy is emerging as a tool for monitoring disease.[4][1] Patients diagnosed in 2025-2026 have more evidence-based options — and more legal avenues for compensation — than at any point in the disease's history. Families affected by asbestos exposure can pursue trust-fund claims and lawsuits with help from an experienced mesothelioma law firm.
At-a-Glance
The 2025-2026 mesothelioma treatment landscape at a glance:
- Three first-line regimens — ASCO 2025 recognizes nivolumab+ipilimumab, pembrolizumab+chemotherapy, and platinum-pemetrexed chemotherapy as standard first-line options.[1]
- 14% five-year survival with immunotherapy — CheckMate 743 reported a 14% five-year overall survival (OS) rate with nivolumab+ipilimumab versus 6% with chemotherapy.[2]
- Lung-sparing surgery preferred — ASCO recommends pleurectomy/decortication (P/D) over extrapleural pneumonectomy (EPP) when surgery is offered, due to lower operative risk.[1]
- MARS2 cautioned against routine surgery — the phase III MARS2 trial found extended P/D plus chemotherapy was associated with worse 2-year survival than chemotherapy alone, intensifying debate over patient selection.[5]
- FDA approved chemoimmunotherapy in 2024 — pembrolizumab plus pemetrexed and platinum was approved September 17, 2024 for unresectable advanced pleural mesothelioma.[3]
- ADI-PEG 20 improved survival in non-epithelioid disease — pegargiminase added to chemotherapy extended median overall survival to 9.3 vs. 7.7 months (hazard ratio 0.71) in the ATOMIC-Meso trial; the biologics license application is under FDA review.[6]
- Germline testing for all patients — ASCO 2025 recommends offering germline (BAP1) testing to every mesothelioma patient; carriers show roughly 7-fold improved long-term survival.[4][1]
- Five emerging therapies in trials — ADI-PEG 20, TTFields, mesothelin CAR-T, the UV1 telomerase vaccine, and volrustomig are advancing through clinical trials.[1]
Key Facts
| Measure | Finding (Source) |
|---|---|
| First-line regimens (2025) | 3 systemic regimens — nivolumab+ipilimumab, pembrolizumab+chemotherapy, platinum-pemetrexed (ASCO Guideline Update, 2025)[1] |
| 5-year overall survival (OS), immunotherapy | 14% vs. 6% chemotherapy — CheckMate 743 five-year follow-up (Scherpereel et al., 2026)[2] |
| Preferred surgery | Pleurectomy/decortication (P/D) over extrapleural pneumonectomy (EPP) — ASCO 2025 (Strong)[1] |
| MARS2 surgical outcome | Extended P/D + chemo worse 2-year OS than chemo alone — MARS2 (Lim, Waller et al., 2024)[5] |
| FDA chemoimmunotherapy approval | September 17, 2024 — pembrolizumab + pemetrexed + platinum (FDA)[3] |
| ADI-PEG 20 (pegargiminase) | Improved survival in non-epithelioid disease; BLA under FDA review — ATOMIC-Meso (Szlosarek et al., 2024)[6] |
| Germline BAP1 mutation survival | ~7-fold improved long-term survival vs. sporadic disease — (Baumann et al., 2015)[4] |
What are the current first-line treatments for mesothelioma?
The March 2025 ASCO guideline update — the first since 2018 — recognizes three first-line systemic regimens for pleural mesothelioma.[1] The choice among them depends primarily on tumor histology (epithelioid versus non-epithelioid).
- Nivolumab + ipilimumab — dual immune checkpoint inhibitor (ICI) therapy. Recommended for all patients and the preferred option for non-epithelioid (sarcomatoid or biphasic) disease.
- Pembrolizumab + pemetrexed + platinum — chemoimmunotherapy approved by the FDA in September 2024; may be offered for epithelioid or non-epithelioid disease.[3]
- Pemetrexed + platinum (± bevacizumab) — chemotherapy, appropriate for epithelioid disease; ASCO advises that chemotherapy alone should not be offered for non-epithelioid disease unless immunotherapy is contraindicated.
ASCO specifically advises that PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) should not be used to guide first-line treatment selection.[1] A detailed breakdown of the landmark immunotherapy data appears on the CheckMate 743 page.
How effective is immunotherapy for mesothelioma?
The CheckMate 743 trial (nivolumab + ipilimumab) established dual checkpoint blockade as a first-line standard of care.[7] In its long-term follow-up, the immunotherapy arm achieved a 14% five-year overall survival (OS) rate versus 6% for chemotherapy — more than double the long-term survival.[2] The benefit was especially pronounced in non-epithelioid disease, the subtype that historically responds poorly to chemotherapy.
Pembrolizumab plus chemotherapy, approved on the basis of the KEYNOTE-483 trial, improved overall survival versus chemotherapy alone and produced an objective response rate (ORR) of roughly 52%.[3] For previously treated patients, single-agent immunotherapy (nivolumab) has also demonstrated a survival benefit over placebo. Immunotherapy is now woven into nearly every line of mesothelioma therapy — a fundamental change from the chemotherapy-only era that preceded 2020.
Which surgery is best for mesothelioma — P/D or EPP?
The long-running debate between pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP) has shifted decisively toward lung-sparing P/D. ASCO 2025 recommends that, when surgery is offered, lung-sparing options should be the first choice because of lower operative and long-term risk; EPP — which removes the entire lung — should be reserved for highly selected patients at centers of excellence.[1]
ASCO also cautions that surgical cytoreduction should not be offered based on anatomic resectability alone, and should be limited to carefully selected patients with early-stage epithelioid tumors. Patients with sarcomatoid histology should not be offered maximal surgical cytoreduction.[1]
This conservative posture reflects the phase III MARS2 trial, which found that extended P/D plus chemotherapy was associated with worse survival at two years than chemotherapy alone, along with more serious adverse events.[5] High-volume surgical centers have contested how broadly MARS2 applies, arguing that careful patient selection at experienced centers yields far lower operative mortality. The practical takeaway for patients is that surgery is now a selectively applied tool, not a default — and where you are treated matters.
What new mesothelioma treatments are in clinical trials?
Five emerging therapies are advancing through the 2025-2026 pipeline. Each has a dedicated canonical page with full trial data and citations:
- ADI-PEG 20 (pegargiminase) — an arginine-depletion therapy that starves tumors lacking the enzyme argininosuccinate synthetase 1 (ASS1). In the ATOMIC-Meso trial, adding pegargiminase to chemotherapy improved survival in non-epithelioid disease, and a biologics license application (BLA) is under FDA review.[6]
- Tumor treating fields (TTFields) — the NovoTTF-100L device delivers alternating electric fields to disrupt cancer-cell division; it carries an FDA Humanitarian Device Exemption based on the STELLAR trial.
- Mesothelin-targeted CAR-T cell therapy — chimeric antigen receptor T cells directed at mesothelin, a protein overexpressed on most mesothelioma tumors, have shown encouraging early-phase activity.
- UV1 telomerase vaccine — a therapeutic cancer vaccine targeting telomerase, under study in combination with immunotherapy.
- Volrustomig (eVOLVE-Meso) — a PD-1/CTLA-4 bispecific antibody being evaluated against standard first-line therapy in the AstraZeneca phase III eVOLVE-Meso trial.
ASCO already includes a conditional recommendation for pegargiminase plus chemotherapy in non-epithelioid patients who are not candidates for immunotherapy, signaling how quickly pipeline agents can reach the guideline.[1]
Why does BAP1 genetic testing matter in 2026?
The 2025 ASCO guideline makes a landmark recommendation: all mesothelioma patients should be offered germline testing — a high-evidence, strong recommendation.[1] The most important gene is BAP1 (BRCA1-associated protein 1). Germline BAP1 mutations cause the BAP1 Tumor Predisposition Syndrome, which raises the risk of mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and other cancers.
Crucially, mesothelioma patients who carry a germline BAP1 mutation show approximately 7-fold improved long-term survival compared with patients who have sporadic mesothelioma.[4] Carriers also tend to develop disease at a younger age and after lower asbestos exposure. ASCO recommends that carriers be screened for secondary cancers and that at-risk family members be offered genetic counseling — and notes that germline testing carries potential medicolegal implications worth discussing. The BAP1 Gene Mutation in Mesothelioma page covers the science and the legal considerations in depth.
Can a blood test detect or monitor mesothelioma?
Blood-based biomarkers and liquid biopsy are an active area of advance. Soluble mesothelin-related peptides (SMRP), measured by the FDA-cleared MESOMARK assay, remain most useful for monitoring disease response rather than for primary diagnosis. Newer approaches — including circulating tumor DNA (ctDNA) and multi-protein proteomic panels — are being studied for earlier detection in asbestos-exposed populations and for tracking response during treatment.
In the perioperative immunotherapy setting, ctDNA has shown practical value: persistent ctDNA during neoadjuvant therapy has been associated with incomplete surgical resection and shorter progression-free survival (PFS).[1] No blood test yet replaces tissue biopsy for diagnosis, but liquid biopsy is steadily becoming part of how mesothelioma is monitored over time.
How is treatment chosen by mesothelioma stage and type?
Treatment selection in 2025-2026 turns less on anatomic stage alone and more on a combination of histology, fitness, and resectability:
- Epithelioid, early-stage, fit patients — may be considered for lung-sparing surgery (P/D) at an experienced center, combined with systemic therapy; immunotherapy or chemoimmunotherapy is standard.
- Non-epithelioid (sarcomatoid/biphasic) disease — nivolumab+ipilimumab is preferred; surgery is generally not recommended for sarcomatoid tumors.
- Advanced or unresectable disease — systemic immunotherapy or chemoimmunotherapy is the backbone, with emerging agents available through clinical trials.
- Recurrent disease — second-line immunotherapy or chemotherapy options apply, and trial enrollment is encouraged.
Because the optimal pathway is individualized, patients benefit from evaluation at a specialized mesothelioma center and from understanding the compensation options that can fund travel to such centers and offset the cost of care.
Frequently Asked Questions
What is the most important mesothelioma treatment advance in 2025-2026? The arrival of immunotherapy as a first-line standard. CheckMate 743 showed that nivolumab plus ipilimumab more than doubled five-year survival (14% vs. 6%) compared with chemotherapy, and ASCO's 2025 guideline now lists three first-line regimens.[2][1]
Is surgery still recommended for mesothelioma? Selectively. ASCO 2025 recommends lung-sparing pleurectomy/decortication over extrapleural pneumonectomy and only for carefully selected early-stage epithelioid patients. The MARS2 trial found that adding extended surgery to chemotherapy worsened two-year survival, so patient selection and surgical center experience are critical.[5][1]
What is ADI-PEG 20 and is it FDA-approved? ADI-PEG 20 (pegargiminase) is an arginine-depletion therapy. In the ATOMIC-Meso trial it improved survival in non-epithelioid mesothelioma when added to chemotherapy. As of 2026, its biologics license application is under FDA review and it is not yet fully approved.[6]
Should I get genetic testing for mesothelioma? ASCO 2025 recommends offering germline testing to every mesothelioma patient. A germline BAP1 mutation is associated with roughly 7-fold better long-term survival and has implications for family members, who may be offered genetic counseling.[4][1]
Can mesothelioma be detected with a blood test? Blood biomarkers such as soluble mesothelin (MESOMARK) are useful for monitoring rather than primary diagnosis. Liquid biopsy approaches like ctDNA are advancing but do not yet replace tissue biopsy. See Liquid Biopsy for Mesothelioma.
Does better treatment affect my legal compensation? Improved survival and new treatments can increase the lifetime medical costs and damages relevant to a claim. An experienced mesothelioma attorney can help document treatment costs and pursue trust-fund claims and lawsuits to recover compensation.
Quick Statistics
- 3 — first-line systemic regimens recognized by ASCO in 2025.[1]
- 14% — five-year overall survival with nivolumab+ipilimumab (vs. 6% chemotherapy) in CheckMate 743.[2]
- 110 — peer-reviewed studies reviewed for the 2025 ASCO guideline update.[1]
- September 17, 2024 — FDA approval date for pembrolizumab + chemotherapy in pleural mesothelioma.[3]
- ~7-fold — improved long-term survival for germline BAP1 mutation carriers vs. sporadic mesothelioma.[4]
- 5 — emerging therapies (ADI-PEG 20, TTFields, CAR-T, UV1 vaccine, volrustomig) in active clinical trials.
- 2018 → 2025 — years between ASCO's prior mesothelioma guideline and its latest update.[1]
- Worse — the 2-year survival outcome of adding extended surgery to chemotherapy in the MARS2 trial.[5]
External Links
- Danziger & De Llano — free case evaluations for mesothelioma and asbestos-related disease, covering asbestos bankruptcy trust-fund claims, civil personal-injury and wrongful-death lawsuits, and VA disability claims for veterans, from a single intake. Call (855) 699-5441 or visit dandell.com/contact-us.
Related Pages
- CheckMate 743 — landmark first-line immunotherapy trial (nivolumab + ipilimumab)
- ATOMIC-Meso Trial — ADI-PEG 20 (pegargiminase) arginine-depletion therapy
- EVOLVE-Meso Trial — volrustomig phase III trial (AstraZeneca)
- UV1 Telomerase Vaccine — therapeutic telomerase vaccine
- CAR-T Cell Therapy — mesothelin-targeted cellular immunotherapy
- Tumor Treating Fields — NovoTTF-100L device therapy
- BAP1 Gene Mutation in Mesothelioma — hereditary risk and germline testing
- Liquid Biopsy for Mesothelioma — blood-based detection and monitoring
- HIPEC — heated chemotherapy for peritoneal mesothelioma
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 Kindler HL, Ismaila N, Bazhenova L, Chu Q, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025. PMID 39778125.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026. PMID 41734361.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 U.S. Food and Drug Administration. FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma. September 17, 2024.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015. PMID 25380601.
- ↑ 5.0 5.1 5.2 5.3 5.4 Lim E, Waller D, Lau K, Steele J, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS2): a phase 3 randomised controlled trial. The Lancet Respiratory Medicine. 2024. PMID 38740044.
- ↑ 6.0 6.1 6.2 6.3 Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, et al. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncology. 2024;10(4):475–483. PMID 38358753.
- ↑ Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375–386. PMID 33485464.